NEW YORK (GenomeWeb) – Biocartis announced today that it has signed a companion diagnostic development agreement with Amgen for its Idylla RAS biomarker tests.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.